SARTORIUS (UNSP.ADS)/1/5 Total Liabilities

Latest as of March 2026: €5.98 Billion EUR ≈ $6.99 Billion USD

SARTORIUS (UNSP.ADS)/1/5 total liabilities. Based on the latest financial reports, SARTORIUS (UNSP.ADS)/1/5 (SRT0) has total liabilities worth €5.98 Billion EUR (≈ $6.99 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See SARTORIUS (UNSP.ADS)/1/5 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Total Liabilities of SARTORIUS (UNSP.ADS)/1/5 (2022–2025)

Total liabilities of SARTORIUS (UNSP.ADS)/1/5 from 2022 to 2025. This chart illustrates how SARTORIUS (UNSP.ADS)/1/5's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are SARTORIUS (UNSP.ADS)/1/5's assets to evaluate the company's liquid asset resilience ratio.

SARTORIUS (UNSP.ADS)/1/5 Competitors by Total Liabilities

The table below lists competitors of SARTORIUS (UNSP.ADS)/1/5 ranked by their total liabilities.

Company Country Total Liabilities
Guidewire Software Inc
NYSE:GWRE
USA $1.18 Billion
Wiwynn Corp
TW:6669
Taiwan NT$292.41 Billion
Erie Indemnity Company
NASDAQ:ERIE
USA $1.09 Billion
GRAB HOLDINGS LTD CL.A
F:A6I
Germany €5.23 Billion
MILLICOM INTL CELL. DL15
F:M4M1
Germany €13.63 Billion
Metso Oyj
HE:METSO
Finland €4.81 Billion
H WORLD GROUP DL-00001
F:CL4
Germany €49.38 Billion
Guangdong Hec Technology Holding Co Ltd Class A
SHG:600673
China CN¥19.13 Billion

Liability Composition Analysis (2022–2025)

This chart breaks down SARTORIUS (UNSP.ADS)/1/5's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SARTORIUS (UNSP.ADS)/1/5 assets under control.

Liquidity & Leverage Metrics

SARTORIUS (UNSP.ADS)/1/5 Total Liabilities Ratios Explained

SARTORIUS (UNSP.ADS)/1/5 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.91 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.19 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.61 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SARTORIUS (UNSP.ADS)/1/5's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SARTORIUS (UNSP.ADS)/1/5 (2022–2025)

The table below shows the annual total liabilities of SARTORIUS (UNSP.ADS)/1/5 from 2022 to 2025.

Year Total Liabilities Change
2025-12-31 €5.85 Billion
≈ $6.84 Billion
-5.73%
2024-12-31 €6.21 Billion
≈ $7.25 Billion
-11.20%
2023-12-31 €6.99 Billion
≈ $8.17 Billion
+61.79%
2022-12-31 €4.32 Billion
≈ $5.05 Billion
--

About SARTORIUS (UNSP.ADS)/1/5

F:SRT0 Germany Medical Instruments & Supplies
Market Cap
$11.40 Billion
€9.75 Billion EUR
Market Cap Rank
#1973 Global
#423 in Germany
Share Price
€56.00
Change (1 day)
+1.82%
52-Week Range
€39.60 - €56.00
All Time High
€125.92
About

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell cult… Read more